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ABSTRACT 22 
Psychiatric disorders are highly heritable and associated with a wide variety of social 23 
adversity and physical health problems. Using genetic liability (rather than phenotypic 24 
measures of disease) as a proxy for psychiatric disease risk can be a useful alternative 25 
for research questions that would traditionally require large cohort studies with long-26 
term follow up. Here we conducted a hypothesis-free phenome-wide association study 27 
in about 300,000 participants from the UK Biobank to examine associations of 28 
polygenic risk scores (PRS) for five psychiatric disorders (major depression (MDD), 29 
bipolar disorder (BP), schizophrenia (SCZ), attention-deficit/ hyperactivity disorder 30 
(ADHD) and autism spectrum disorder (ASD)) with 23,004 outcomes in UK Biobank, 31 
using the open-source PHESANT software package. There was evidence after 32 
multiple testing (p<2.55x10-06) for associations of PRSs with 294 outcomes, most of 33 
them attributed to associations of PRSMDD (n=167) and PRSSCZ (n=157) with mental 34 
health factors. Among others, we found strong evidence of association of higher 35 
PRSADHD with 1.1 months younger age at first sexual intercourse [95% confidence 36 
interval [CI]: -1.25,-0.92] and a history of physical maltreatment; PRSASD with 0.01% 37 
lower erythrocyte distribution width [95%CI: -0.013,-0.007]; PRSSCZ with 0.95 lower 38 
odds of playing computer games  [95%CI:0.95,0.96]; PRSMDD with a 0.12 points higher 39 
neuroticism score [95%CI:0.111,0.135]  and PRSBP with 1.03 higher odds of having a 40 
university degree [95%CI:1.02,1.03]. We were able to show that genetic liabilities for 41 
five major psychiatric disorders associate with long-term aspects of adult life, including 42 
socio-demographic factors, mental and physical health. This is evident even in 43 
individuals from the general population who do not necessarily present with a 44 
psychiatric disorder diagnosis.  45 
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AUTHOR SUMMARY 46 
Psychiatric disorders are associated with a wide range of adverse health, social and 47 
economic problems. Our study investigated the association of genetic risk for five 48 
common psychiatric disorders with socio- demographics, lifestyle and health of about 49 
330,000 participants in the UK Biobank using a systematic, hypothesis-free approach. 50 
We found that genetic risk for attention deficit/hyperactivity disorder (ADHD) and 51 
bipolar disorder were most strongly associated with lifestyle factors, such as time of 52 
first sexual intercourse and educational attainment. Genetic risks for autism spectrum 53 
disorder and schizophrenia were associated with altered blood cell counts and 54 
decreased risk of coeliac disease, respectively. Increased genetic risk for depression 55 
was associated with other mental health outcomes such as neuroticism and irritability. 56 
In general, our results suggest that genetic risk for psychiatric disorders associates 57 
with a range of health and lifestyle traits that were measured in adulthood, in 58 
individuals from the general population who do not necessarily present with a 59 
psychiatric disorder diagnosis. However, it is important to note that these associations 60 
are not necessary causal but can also represent genetic correlation or be influenced 61 
by other factors, such as socio-economic factors and selection into the cohort. The 62 
findings should inform future research using causally informative designs. 63 
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INTRODUCTION 64 
Family and twin research as well as large-scale genome-wide association studies 65 
(GWAS) have shown that psychiatric disorders are highly heritable [1] and that genetic 66 
risks for psychiatric disorders are associated with socio-economic factors, physical 67 
health outcomes as well as other psychiatric disorders [2-5]. Using genetic liability 68 
(rather than phenotypic measures of disease) as a proxy for psychiatric disease risk 69 
can be a useful alternative for research questions that would traditionally require long-70 
term follow up and big datasets due to the low prevalence of some of the psychiatric 71 
disorders of interest in the population (e.g. adult-onset health consequences of child 72 
neurodevelopmental disorders). In addition, while high genetic risk for a psychiatric 73 
disorder is not always indicative of a diagnosis of psychiatric disease, it can index 74 
underlying subthreshold symptomatology that can still impact later adversities and 75 
quality of life [6]. Furthermore, psychiatric diagnosis may not always be available in 76 
any cohort, e.g. there are only very few self-reported diagnosis of Attention 77 
deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) or 78 
schizophrenia (SCZ) available in the UK Biobank sample, which would make  direct 79 
comparisons between participants with and without a diagnosis impossible. 80 
So far, studies have used hypothesis-driven approaches to investigate associations of 81 
genetic risk for psychiatric disorders with various psychiatric and health outcomes as 82 
well as lifestyle factors [7,8]. However, big data resources that are readily available, 83 
such as UK Biobank with about 500,000 participants, provide rich phenotypic 84 
information that can be used for hypothesis-free studies and offset the multiple testing 85 
burden. Phenome-wide association studies (pheWAS) are a type of hypothesis-free 86 
analysis where the association of a trait of interest is systematically tested with a 87 
potentially large number of phenotypes and can be hypothesis-generating by 88 
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identifying an association when there is no prior reason to expect that an association 89 
may exist. As all available phenotypes are tested and the less ‘significant’ results 90 
published alongside those of greater ‘significance’, pheWAS can help to reduce biases 91 
associated with hypothesis-driven studies where researchers might only publish the 92 
most desirable or expected results.  93 
In a Polygenic Risk Score (PRS) pheWAS (PRS-pheWAS) genetic risk is used as a 94 
proxy for lifelong liability for a disorder to explore associations of this genetic liability 95 
with a broad range of traits. Understanding these associations will be essential to 96 
inform prevention or early intervention strategies. However, conclusions about 97 
causality are limited due to the low predictive power and high pleiotropic effects of 98 
genetic risk scores for psychiatric conditions [8]. 99 
The aim of this study was to investigate the associations between genetic risk for five 100 
common psychiatric disorders – attention-deficit/ hyperactivity disorder (ADHD), 101 
autism spectrum disorder (ASD), schizophrenia (SCZ), major depression (MDD) and 102 
bipolar disorder (BP) - with a wide range of socio-demographic, lifestyle, physical and 103 
mental health outcomes in UK Biobank, using the systematic hypothesis-free PRS-104 
pheWAS approach.  105 
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RESULTS 106 
In total 334,976 participants of white British ancestry in UK Biobank were included in 107 
this study with an average age of 56 (standard deviation [SD]=8) years. A descriptive 108 
overview of selected UK Biobank study sample characteristics is given in Fig 1A. The 109 
UK Biobank participants are known to be more educated and healthier than the 110 
average UK population which is reflected in the high percentage of people with a 111 
university degree (47%) and low prevalence of current smoking (10%) in the sample, 112 
which is comparable to the full UK Biobank release [9]. Furthermore, 34% of 113 
participants reported to have seen a general practitioner and 11% a psychiatrist for 114 
nerves, anxiety, tension or depression but there are few self-reported cases of 115 
schizophrenia (n=132), ADHD (n=71), ASD (n=143) or bipolar disorder (n=439). An 116 
overview of UK Biobank phenotype categories is given in Fig 1B. 117 
Fig 1. Study overview. (A) Descriptive sample overview of selected outcomes in UK 118 
Biobank. (B) Categories of UK Biobank with the size of pie chart sections indicating 119 
the number of included outcomes: socio-demographics (n=2,057), general health 120 
(n=19,740), mental health (n=233), brain and cognition (n=974). 121 
The low number of self-reported ADHD, ASD, schizophrenia and bipolar disorder 122 
cases did not allow a direct test of predictive power for the respective PRS and we 123 
relied on the predictive accuracy reported in other studies [10-14]. The broad 124 
question whether participants have “Seen a psychiatrist for nerves, anxiety, tension 125 
or depression” was predicted by the PRSMDD (OR: 1.09 [95% confidence interval [CI]: 126 
1.08,1.10] p=5x10-52) and PRSSCZ (OR: 1.05 [95% CI:1.04,1.06] p=2x10-17). 127 
DISORDER SPECIFIC EFFECTS 128 
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The PRS-pheWAS of each psychiatric disorder tested the association of the respective 129 
polygenic risk score, aggregated from independent, genome-wide significant SNPs, 130 
with 23,004 outcomes in UK Biobank, adjusted for age, sex and the first 10 genetic 131 
principal components. There was strong evidence after multiple testing correction 132 
based on the number of independent tests derived from spectral decomposition 133 
(p<2.55x10-6) for associations of either the ADHD, ASD, SCZ, MDD or BP PRS with 134 
294 outcomes in 37 UK Biobank categories (Fig 2 and S1 Table) as described below. 135 
Of those, 290 outcomes also pass the more stringent Bonferroni threshold (2.17x10-136 
6). Correlations among the PRS can be found in supplementary S2 Table. A detailed 137 
list of all PRS-pheWAS results generated by the open-source PHESANT software 138 
package can be found in S3 Table. Unless stated as a PHESANT result, estimates for 139 
continuous outcomes were generated by follow-up linear regressions to compute 140 
estimates on their original scale, as PHESANT automatically applied an inverse 141 
normal rank conversion to all continuous outcomes. 142 
Fig 2. Overview of the distribution of disorder specific polygenic risk scores (p<5x10-143 
8) associated outcomes per category of the UK Biobank variables catalogue. Shown 144 
are the number of associations with polygenic risk scores for attention 145 
deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), schizophrenia 146 
(SCZ), major depression (MDD) and bipolar disorder (BP). 147 
Attention deficit/ hyperactivity disorder 148 
PRSADHD was strongly associated with 74 outcomes (Fig 3) including 36 socio-149 
demographic factors, 32 general health and 6 mental health, brain and cognition 150 
outcomes. The strongest evidence of association with PRSADHD was seen for socio-151 
demographic and lifestyle factors. 1 SD higher PRSADHD was associated with a 152 
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1.09 month younger age at first sexual intercourse [95% CI: -1.25,-192] (p=2.0x10-16), 153 
and 0.96 lower odds of having a university degree [95% CI: 0.95, 0.97] (p=1.7x10-29). 154 
In addition, higher PRSADHD was associated with younger age of their parents (-0.08 155 
years [95%CI: -0.102,-0.050] p=5.1x10-9; -0.10 years [95% CI: -0.136,-0.069] 156 
p=1.9x10-9,respectively), 0.97 lower odds of average household income [95%CI: 157 
0.96,0.98] (p=5.7x10-20), 1.05 higher odds of current smoking [95%CI :1.03,1.06] 158 
(p=5.7x10-15) and 1.04 higher odds of experiencing physical abuse as a child [95%CI: 159 
1.02,1.06] (p=4.4x10-6). 160 
Fig 3. PRS-PheWAS results for attention deficit/hyperactivity disorder (ADHD), autism 161 
spectrum disorder (ASD), schizophrenia (SCZ), major depressive disorder (MDD) and 162 
bipolar disorder (BP). Left hand panel: QQ plots of expected versus observed p-values 163 
for association of PRS with all outcomes in UK Biobank. Red line indicates the 164 
significance threshold derived by spectral decomposition (2.5x10-6). Right hand panel: 165 
selected results from different categories with p-values below the significance 166 
threshold and estimates generated by PHESANT. Results for continuous outcomes 167 
(std. β) are the standard deviation change of inverse-rank normal transformed 168 
outcome per 1 SD higher PRS. 169 
Further, 1 SD increase in PRSADHD was associated with 15 physical health outcomes 170 
related to obesity, including 0.05 kg/m2 higher BMI [95%CI: 0.036,0.089] (p=1.7x10-10), 171 
leg and arm fat mass, waist circumference and trunk fat mass. Furthermore, there was 172 
evidence for an association of PRSADHD with blood measures, such as 0.02 cells/L 173 
higher leukocyte count [95%CI: 0.011,0.025] (p=2.5x10-7). 174 
Associations seen for brain and cognition include 0.04 points lower fluid intelligence 175 
score [95%CI: -0.051,-0.026] (p=1.9x10-9). 176 
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Autism spectrum disorder 177 
PRSASD was strongly associated with 10 outcomes (Fig 3), including 1 socio-178 
demographic, 8 general health and 1 mental health outcome. 179 
The strongest association of PRSASD was found for lower erythrocyte distribution width 180 
where 1 SD higher PRSASD associated with 0.01% lower erythrocyte distribution width 181 
[95% CI: -0.013, -0.007] (p=6.3x10-10) and 0.98 lower odds of comparative body size 182 
at age 10 [95%CI:0.97,0.98] (p=6.6x10-11). Furthermore, 1 SD higher PRSASD was 183 
associated with 0.001 g/cm2 lower heel bone mineral density (BMD) [95%CI:-0.002,-184 
0.001] (p=4.0x10-5).  185 
The only mental health outcome that was associated with PRSASD was 1.02 higher 186 
odds of being a nervous person (“suffer from nerves”) [95%CI:1.01,1.03] (p=7.9x10-7). 187 
Schizophrenia 188 
There was strong evidence of association for PRSSCZ with 157 outcomes (Fig 3), 189 
including 33 socio-demographic, 72 mental health and cognition and 52 general health 190 
outcomes. 191 
The strongest evidence of an association with higher PRSSCZ was detected for time of 192 
completing an online cognitive function test (pairs matching) (OR:188msec 193 
[95%CI:146,229] p=<2.2x10-16) ,1.06 higher odds of experiencing tense 194 
feelings[95%CI:1.05,1.07] (p=3.2x10-37) and 0.95 lower odds of playing computer 195 
games  [95%CI:0.95,0.96] (p=7.6x10-30). 196 
In addition, a 1 SD increased PRSSCZ was associated with 1.05 higher odds of 197 
consulting a psychiatrist for nerves, anxiety, tension or depression [95%CI:1.04,1.06] 198 
(p=1.6x10-17).  199 
Major depressive disorder 200 
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PRSMDD was associated with 167 outcomes (Fig 3), including 21 socio-demographic, 201 
84 mental health and 62 general health outcomes. 202 
Most of the associations (74%) were related to mental health, including an association 203 
of higher PRSMDD with higher odds of depression, anxiety, irritability, nervousness and 204 
mood swings. Strongest evidence of association with PRSMDD was found for 1.08 205 
higher odds of “seen a doctor for nerves, anxiety, tension or depression” 206 
[95%CI:1.08,1.09] (p=2.7x10-106), 0.12 points higher neuroticism score 207 
[95%CI:0.11,0.14] (p=2.0x10-16) and 1.06 higher odds of having mood swings 208 
[95%CI:1.05,1.07] (p=9.8x10-58). 209 
Furthermore, there was strong evidence of 1 SD higher PRSMDD being associated with 210 
socio-demographic and lifestyle traits including 1.03 higher odds of ever smoking 211 
[95%CI:1.02,1.03] (p=1.5x10-13) and 1.05 higher odds of cannabis use 212 
[95%CI:1.03,1.06] (p=4.1x10-10). 213 
Associated physical health measures included 1.03 higher odds of taking medication 214 
for pain relief, constipation or heartburn, e.g. paracetamol [95%CI:1.03,1.04] 215 
(p=4.4x10-11) and 1.02 odds of more frequent feelings of pain, e.g. back pain 216 
[95%CI:1.02,103] (p=1.1x10-9). 217 
Bipolar disorder 218 
PRSBP was associated with 20 outcomes (Fig 3), including 3 socio-demographic, 14 219 
general health and 3 mental health outcomes. 220 
Socio-demographic and lifestyle factors included associations of higher PRSBP with 221 
1.03 higher odds of having a university degree [95%CI:1.02,1.03] (p=2.4x10-12), 0.02 222 
hours/day less time spent watching television [95%CI:-0.021,-0.010] (p=2.8x10-8) and 223 
0.97 lower odds of playing computer games [95%CI:0.97,0.98] (p=1.1x10-9). 224 
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General health traits included 11 traits indicating an association of 1 SD higher PRSBP 225 
with 0.06kg/m2 lower body weight and fat mass [95%CI:-0.07,-0.04] (p=1.6x10-11) and 226 
2 traits related to blood measures, such as 0.005% decreased platelet distribution 227 
width [95%CI:-0.006,-0.003] (p=3.1x10-7). 228 
Two traits related to mental health were nervous (OR:1.02 [95%CI:1.01,1.03] 229 
p=2.3x10-7) and tense feelings (OR:1.02 [95%CI:1.01,1.03] p=8.0x10-7). 230 
CROSS DISORDER CONSIDERATIONS 231 
The highest overlap of associated outcomes of the univariable PRS-pheWAS scans 232 
was seen between schizophrenia and depression (22 general health, 44 mental health 233 
and 9 sociodemographic outcomes in common), bipolar disorder (12 general health, 234 
3 mental health and 2 sociodemographic outcomes in common) and ADHD (18 235 
general health, 1 mental health, 2 brain & cognition and 4 sociodemographic outcomes 236 
in common). Large overlap was also seen between ADHD and MDD ( 22 general 237 
health, 3 mental health and 4 socio-economic outcomes) and BP (2 socio-economic 238 
and lifestyle and 7 general health outcomes) (Fig 4). However, the majority of the 239 
associations are directionally opposite for ADHD and BP. For example, higher 240 
PRSADHD showed evidence for associations with lower educational attainment and 241 
higher BMI, whereas higher PRSBP was associated with higher educational attainment 242 
and lower BMI.  243 
Fig 4. Cross-disorder comparison. Shown are standardized log odds (upper section in 244 
each panel) or standardized beta-values (lower section of each panel) of all outcomes 245 
associated with polygenic risk scores for either attention deficit/hyperactivity disorder 246 
(ADHD), autism spectrum disorder (ASD), schizophrenia (SCZ), major depressive 247 
disorder (MDD) or bipolar disorder (BP) at p<2.55x10-6 as indicated by stars (*). For 248 
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outcomes categorized as ordered-logistic, only one outcome is displayed. Only 249 
associations with anthropometric measures of the right side of the body are shown. 250 
Estimates were generated by PHESANT. Results for continuous outcomes (std. beta) 251 
are the standard deviation change of inverse-rank normal transformed outcome per 1 252 
SD higher PRS. 253 
Furthermore, all disorder PRSs showed some evidence for association with different 254 
blood cell counts, such as a decreased leukocyte count for PRSADHD and PRSMDD, or 255 
a decreased eosinophil count for PRSADHD and PRSSCZ. 256 
There was very little overlap of highly associated outcomes between the 257 
neurodevelopmental domains (ADHD and ASD). 258 
SENSITIVITY ANALYSIS 259 
We repeated our tests of association for outcomes passing the spectral decomposition 260 
threshold, additionally adjusting for additional potential confounders (assessment 261 
centre, genotype chip and the first 40 principal components). These have not been 262 
included in the original analysis to reduce the possibility of them introducing collider 263 
bias. Estimates were highly consistent with our main results, as shown in S4 and S5 264 
Table. 265 
Relaxing the p-value threshold for including SNPs in the PRS resulted in some 266 
changes in the results (S1 Fig). For ADHD, SCZ, MDD and BP the general trend was 267 
an inflation of p-values (S6 Table) and higher effect estimates with smaller confidence 268 
intervals. A different pattern was observed for autism spectrum disorder with 269 
inconsistent results for some of the outcomes, as described in detail in the 270 
supplementary S1 Text. Overall the strength of associations obtained for blood cell 271 
13 
 
count traits across disorders varied between p-value thresholds, with weaker 272 
associations found for less stringent p-value thresholds. 273 
When applying the more stringent Bonferroni correction for multiple testing we found 274 
that the number of strongly associated outcomes with the PRS reduced slightly to 71 275 
outcomes for PRSADHD, 9 for PRSASD, 155 for PRSSCZ, 166 for PRSMDD and 19 for 276 
PRSBP. Outcomes that do not pass Bonferroni but phenoSPD are “Weight”, “Trunk fat 277 
mass” and “Forced expiratory volume in 1 second” for ADHD; “Forced vital capacity 278 
(FVC)” for ASD; “Word interpolation” and “Valsartan prescription” for SCZ; “Action 279 
taken following self-harm” for MDD and “Spherical power (left)” for BP. 280 
In order to reduce potential biases due to sample overlap with the MDD GWAS from 281 
Wray et al. [5], we computed a PRS based on the Wray et al. sample excluding UK 282 
Biobank and 23andMe participants (PRSMDDnoUKB). The corresponding pheWAS 283 
resulted in 51 outcomes passing the multiple testing threshold (S7 Table). Overall, 284 
effect estimates were attenuated for many previously identified outcomes and about 285 
one third of them do not pass the multiple testing threshold anymore. On the other 286 
hand, new associations especially with anthropometric traits could be observed. 287 
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DISCUSSION 288 
In this study, we conducted a PRS-pheWAS to examine the relationships between 289 
genetic liability for five major psychiatric disorders and 23,004 outcomes in about 290 
300,000 UK Biobank participants. 291 
Our results build on a large body of literature supporting links between genetic risk for 292 
psychiatric disorders with a wide variety of outcomes including psychological well-293 
being, lifestyle, socio-demographic factors and physical health [2,4,7,15,16]. Our 294 
findings also suggest that although psychiatric disorders show strong genetic overlap 295 
[7], genetic risk for distinct psychiatric disorders show differential associations with 296 
lifestyle, socio-demographic factors and physical health as highlighted in Fig 5. 297 
Genetic liability for ADHD and bipolar disorder showed the strongest associations with 298 
lifestyle and social environmental factors as well as physical health. On the other hand, 299 
genetic liability for major depression and schizophrenia was most strongly associated 300 
with psychological health and associations with lifestyle and socio-demographic 301 
factors were less robust. 302 
Fig 5. Categories of highly associated outcomes with polygenic risk scores for 303 
attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), 304 
schizophrenia (SCZ), major depressive disorder (MDD) and bipolar disorder (BP). Size 305 
of categories depends on the relative number of associated outcomes to the total 306 
number of outcomes within each category. Only categories with more than 1 variables 307 
are shown. Lifestyle and socio-demographic factors are shown in orange, physical 308 
health measures are shown in green and mental health, brain and cognition traits are 309 
shown in violet. Grey categories had zero hits for the corresponding disorder. 310 
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We were able to replicate previously reported associations between genetic liability 311 
for ADHD and lower educational attainment [17,18], higher prevalence of smoking 312 
[19], younger age at delivery [20] and higher body mass index [21]. While the previous 313 
findings for smoking and BMI were identified in young adults, our findings using an 314 
adult population-based sample with a mean age of 56 years, suggest that associations 315 
of childhood psychiatric disorder genetic liabilities with health and social outcomes 316 
persist into later adulthood. Associations of genetic liability for ADHD in childhood 317 
could represent effects of childhood ADHD or sub-threshold ADHD on long-term social 318 
and economic outcomes, or alternatively associations could be due to parental effects 319 
or horizontal pleiotropy (the same genetic variants affecting multiple traits). Hence, 320 
some of the observed associations in this study might also be more likely to act as a 321 
risk factor for the corresponding disorder, rather than being the consequence of it.  322 
Interestingly ADHD genetic liability also was associated with a history of physical 323 
maltreatment. This result adds to findings from previous twin and adoption designs 324 
that have suggested that ADHD and ADHD genetic liability may have “evocative” 325 
effects on parent-child hostility [22-24].  326 
Many of the associations of genetic liability for MDD with increased mood swings, 327 
irritability, feelings of loneliness and isolation are clinically known and have previously 328 
been reported [5]. Our results are also in line with a recent publication from the 329 
Brainstorm consortium investigating genetic correlations among psychiatric disorders 330 
with neurological and quantitative traits using LD score regression and GWAS 331 
summary statistics, reporting high genetic correlations between most psychiatric 332 
disorders and educational attainment and BMI [2,7]. However, we found little evidence 333 
for associations of genetic liability for ADHD and ASD with mental health outcomes, 334 
such as depressive symptoms, neuroticism or anxiety; and very few associations with 335 
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cognitive or brain imaging outcomes, which might be because of the UK Biobank being 336 
a selected sample with lower rates of psychiatric disorders than the general population 337 
as discussed in the limitations section. 338 
In addition to identifying previously reported associations, our PRS-pheWAS also 339 
revealed novel associations. We found a strong association of genetic liability for ASD 340 
with decreased heel bone mineral density, which furthers previous evidence from 341 
observational studies that children and adolescents with ASD have lower bone mineral 342 
density [25,26], higher frequency of bone fractures [27] and lower vitamin D levels 343 
[28,29], which is essential for bone metabolism. This might suggest that these 344 
observed associations may be due to pleiotropic effects of genetic variants associated 345 
with bone health. 346 
In line with our results, other previous work in schizophrenia patients and their relatives 347 
identified an association between schizophrenia and longer performance duration on 348 
the Trail Making Test [30], which requires searching and connecting irregularly 349 
arranged targets (digits and letters) in ascending order and is widely used to test for 350 
executive function, cognitive ability and processing speed [31-36]. 351 
Altered blood cell counts were associated with genetic liability for all disorders. Many 352 
psychiatric disorders have been previously associated with allergic or inflammatory 353 
states [37-39], such as asthma [40] and atopic diseases [41,42] but it is unclear 354 
whether high inflammatory states are on the causal pathway to disorder manifestation 355 
or the result of comorbid and confounding behaviours associated with the disease, 356 
such as restricted diet, overweight, risky behaviours or medication. Our results support 357 
the possibility that altered blood cell counts could be a consequence of the disorder, 358 
but we cannot rule out contributions of horizontal pleiotropic effects that weaken or 359 
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intensify the observed association when adding more SNPs into the PRS. Also, 360 
considering the inconsistent findings from the sensitivity analyses for blood count 361 
traits, results need further validation and should be treated with caution. 362 
In addition to previous observations between psychiatric disorders and later outcomes 363 
that we were able to identify in our pheWAS, there are many reported and established 364 
associations that we did not observe in our study. For example, we did not observe an 365 
association between genetic risk for our psychiatric disorders, apart from a negative 366 
association with PRSSCZ, and type 2 diabetes mellitus (T2D). Reasons for this lack of 367 
observations may include selection bias as discussed in the next paragraph, 368 
confounding of observational studies or complex relationships between disorders. 369 
Although there is evidence of genetic overlap between  T2D and SCZ [43] the causal 370 
pathway is potentially complex and bidirectional, and needs to be investigated using 371 
a formal causal framework. However, being able to identify true causal relationships 372 
and shared biological pathways between psychiatric disorders and other health or 373 
socio-economic outcomes is essential in designing interventions. Hence, we 374 
encourage researchers to triangulate our findings using other causally informative 375 
studies.  376 
Limitations 377 
Patients with psychiatric disorders or high genetic liability for psychiatric disorders are 378 
known to be less likely to participate in studies in the first place and more likely to drop-379 
out during an ongoing study [44]. Selection into a study as well as attrition can induce 380 
collider bias [45]. There is consensus that the UK Biobank sample is not representative 381 
of the UK population, with participants showing, for example, lower prevalence of 382 
current smoking and lower rates of mortality [9]. If both having a psychiatric disorder 383 
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and a specific outcome (e.g. high socio-economic position) are associated with 384 
participation (the collider), this can induce an association between genetic risk for 385 
psychiatric disorders and the outcome (S2 Fig). Supplementary S8 Table provides an 386 
overview of the expected direction of the collider bias on the effect estimates for a 387 
simple model with positive or negative association with participation of the exposure 388 
or outcome variable, which can be used as a guide to expected direction of bias under 389 
some circumstances.  390 
A direct comparison of PHESANT estimates across the psychiatric disorders cannot 391 
be done without taking the differentially powered GWASs and derived PRS into 392 
account. This can affect the number and set of outcomes associated with each 393 
disorder, which only allows for a relative comparison among the PRS. We also cannot 394 
calculate the predictive power of the ADHD, ASD, schizophrenia and bipolar PRS in 395 
the UK Biobank sample due to very low number of self-reported diagnoses of these 396 
disorders. Further, the MDD GWAS used in the current study to calculate genetic risk 397 
scores included thirty thousand participants from UK Biobank (about 10% of the 398 
GWAS sample) which might have inflated our results for depression related items but 399 
is not expected to introduce bias in any other traits, such as blood counts. However, 400 
sensitivity analysis using a GWAS excluding the UK Biobank sample and hence much 401 
smaller sample size did confirm many of the found observations. 402 
Although genetic risk scores were derived using variants associated at genome-wide 403 
significance level, they can still have horizontal pleiotropic effects on different 404 
disorders and traits. Hence, our reported associations cannot on its own inform about 405 
causality but should be followed up with other causally informative methods to assess 406 
the true direction of the causal effect as well as pleiotropy and heterogeneity between 407 
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genetic variants. We therefore encourage triangulation of results using other study 408 
designs [46,47], such as two-sample MR, negative control or twin studies.  409 
Conclusion 410 
We were able to show that genetic liability for five common psychiatric disorders is 411 
associated with distinct domains of adult life, including socio-demographic factors, 412 
mental and physical health. This is evident even in individuals from the general 413 
population who do not necessarily present with a psychiatric disorder diagnosis, or for 414 
individuals who may have been diagnosed as a child but whose symptoms have 415 
decreased since. Our research has potential implications for both risk factors and 416 
consequences of mental health problems. Our findings indicate potential factors 417 
associated with genetic liability for psychiatric disorders, including some which have 418 
been identified before (e.g. irritability and depression) and also novel hypotheses (e.g. 419 
the association of genetic risk for ASD and reduced bone mineral density) that could 420 
be tested using different study designs. Finally the findings also support well-421 
established research into the high long-term economic, societal and individual costs 422 
associated with mental health problems [48] and highlight that it is important for mental 423 
health scientists and clinicians to consider a broad range of lifestyle, socio-424 
demographic and health risks beyond core diagnoses, in those at elevated 425 
familial/genetic risk as well as those with a psychiatric disorder. 426 
20 
 
METHODS 427 
Ethics Statement 428 
UK Biobank received ethical approval from the research ethics committee (reference 429 
13/NW/0382). All participants provided informed consent to participate. This work was 430 
done under application number 16729 (using genetic data version 3 and phenotype 431 
dataset 21753).  432 
Study population 433 
Between 2006-2010 UK Biobank recruited 503,325 men and women in the England, 434 
Wales and Scotland at ages 40-69 years. The cohort contains a large dataset including 435 
physical measurements, blood/urine/saliva samples, health and lifestyle 436 
questionnaires as well as genotype (https://www.ukbiobank.ac.uk/). 437 
For 463,010 participants genotyping was performed using the Affymetrix UK BiLEVE 438 
Axiom array or Affymetrix UK Biobank Axiom array. Participants with non-white British 439 
ancestry, defined as a self-reported non-white British ancestry in combination with a 440 
genetic principal component analysis (PCA) analysis conducted by UK Biobank 441 
(n=54,757 non-white British or non-Caucasian) [49], and participants who had a 442 
kinship coefficient denoting a third-degree relatedness (based on Manichaikul et al. 443 
[50]; kinship coefficient < 0.0625, n=73,277) were removed from an already quality 444 
checked dataset (excluding participants with withdrawn consent, sex mismatch or sex 445 
aneuploidy) [49,50], resulting in a dataset containing 334,976 participants (Fig 6). 446 
Fig 6. Overview of study sample derivation. Participants with withdrawn consent, sex 447 
mismatch or sex aneuploidy where already removed from the dataset in standard QC 448 
steps. [49] 449 
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Polygenic risk scores 450 
Genetic variants were identified from the most recent GWAS summary statistics listed 451 
in Table 1 with p<5x10-8 for ADHD, ASD, SCZ, MDD and BP. This stringent p-value 452 
cut-off was chosen to minimize bias introduced by horizontal pleiotropic effects of 453 
genetic variants. All summary statistics were subject to standard quality control 454 
including filtering for minor allele frequency (MAF>0.1) and imputation quality 455 
(INFO>0.8) and excluding the MHC region on chromosome 6 (26-33Mb) due to its 456 
complex linkage disequilibrium structure. Polygenic risk scores (PRS) were derived 457 
using independent risk alleles at p<5x10-8 in approximate linkage disequilibrium 458 
(R2<0.1 within 500kb distance) and computing a weighted, standardized mean score 459 
from these, as has been described previously [51,52]. 460 
Table 1. Details of GWAS used for calculating PRS  461 
disorder cases controls SNPs in PRS1 Heritability Source 
ADHD 20,183 35,191 10 5.5%2 Demontis et al. (2019) [2]  
ASD 18,381 27,969 2 2.5%2 Grove et al. (2017) [4] 
Schizophrenia 36,989 113,075 99 7%3 Ripke et al. (2014) [3] 
MDD 135,458 344,901 44 1.9%3 Wray et al. (2018) [5] 
Bipolar 
disorder 20,129 21,524 8 4%
3
 
Ruderfer et al. (2018) [53] 
1- PRS derived from genome-wide significant hits (p<5x10-8) 462 
2- SNP heritability estimates (Nagelkerke’s R2) reported in the corresponding discovery sample 463 
3-Percent of variance on the liability scale explaines by PRS reported in corresponding discovery sample 464 
ADHD – Attention deficit/hyperactivity disorder, MDD – Major depression, ASD – Autism spectrum disorder 465 
Outcomes 466 
UK Biobank provides a fully searchable data showcase 467 
(http://biobank.ctsu.ox.ac.uk/crystal/) which at the time of data download (March 2018) 468 
included 23,004 outcomes (see supplementary S2 Text), including lifestyle and 469 
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environment, socio-demographic, early life factors, anthropometry, family history and 470 
depression outcomes. 471 
Age, sex and the first 10 principal components derived from the genetic data were 472 
included as covariates in all regression models. Age was derived from the participants 473 
date of birth and the date of their first assessment centre visit. Sex was self-reported 474 
and validated using genetic data. 475 
PHESANT PRS-pheWAS 476 
PHESANT package (version 0.17) was used to test the association of each PRS with 477 
each outcome variable in Biobank. A detailed description of PHESANT’s automated 478 
rule-based method is given elsewhere [54,55]. In brief, decision rules are based on 479 
the variable field type and categorize each variable as one of four data types: 480 
continuous, ordered categorical, unordered categorical or binary. PHESANT then 481 
estimates the univariate association of the PRS (independent) with each outcome 482 
variable (dependent) in a regression model, respectively. Normality of continuous data 483 
is ensured by an inverse normal rank transformation prior to testing. To compute 484 
meaningful and better interpretable estimates, outcomes passing the multiple testing 485 
threshold that qualified as continuous outcomes were followed up on their original 486 
scale using a linear regression, excluding outliers and checking for normal distribution 487 
of residuals.  All estimates correspond to 1 SD change of the PRS. 488 
PHESANT assigns each UK Biobank outcome to one of 91 level 3 categories based 489 
on the 235 origin categories of the UK Biobank catalogue (a full list of categories is 490 
provided in S1 Table). Furthermore, three authors (BL, EW, ES) grouped these 91 491 
categories into four prespecified higher level categories in order to aid result 492 
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presentation: socio-demographics and lifestyle, brain and cognition, mental health and 493 
general health (Fig 1B). 494 
To account for multiple testing (n=23,004 tests) we used a previously derived threshold 495 
[55,56] based on an estimate of the number of independent phenotypes calculated 496 
using spectral decomposition (phenoSPD) (n=19,645). The multiple testing adjusted 497 
significance threshold was p<2.55x10-6 (0.05/19,645). The amount of inflation of 498 
observed versus expected p-values is given as the ratio of the median chi-squared 499 
statistics for observed to expected median p-values, referred to as Lambda (λ). A 500 
conservative Bonferroni correction of multiple testing that assumes uncorrelated traits, 501 
would yield a similar p-value threshold of p<2.17x10-6 (0.05/23,004). 502 
PHESANT sensitivity analysis 503 
Analyses were re-run to assess residual confounding of assessment centre and 504 
genetic batch, including them as well as all 40 principal components as additional 505 
covariates for outcomes identified as strongly associated with either one of the 506 
disorders PRS. These covariates were not included in the first model because this 507 
could introduce collider bias if, for example, location of assessment centre is affected 508 
by both genetic predisposition and outcomes, as discussed in the limitations section. 509 
Furthermore, PRS were derived using various p-value thresholds (p<0.01, p <0.1x10-3, 510 
p<1x10-4, p<1x10-5, p<1x10-6) with consequently increasing numbers of SNPs (S9 and 511 
S10 Table) and the five PRS-pheWAS were re-run with the more relaxed PRS to 512 
capture a larger amount of explained variation in the disorders by accepting an 513 
increase in horizontal pleiotropic effects and adjunct noise. For MDD GWAS results 514 
were available for only 10,000 SNPs at these additional thresholds due to availability 515 
restrictions. 516 
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To assess biases due to a sample overlap between the Wray et al. MDD GWAS and 517 
UK Biobank, we computed a PRS based on the Wray et al. sample excluding the UK 518 
Biobank and 23andMe samples (43,204 cases and 95,680 controls, nSNPs in PRS=3) 519 
as described in Howards et al. [57] and re-run the pheWAS based on this. 520 
All analyses were performed in R version 3.2.4 ATLAS and R version 3.3.1, and the 521 
code is available at [https://github.com/MRCIEU/Psychiatric-disorder-pheWAS-522 
UKBB]. Git tag v0.2 corresponds to the version presented here.  523 
25 
 
ACKNOWLEDGEMENTS 524 
This research was conducted using the UK Biobank resource under application 525 
number 16729. We acknowledge the members of the Psychiatric Genomics 526 
Consortium (PGC) and The Lundbeck Foundation Initiative for Integrative Psychiatric 527 
Research (iPSYCH) for the publicly available data used as the discovery samples in 528 
this article. Further we want to acknowledge Sean Harrison for providing the polygenic 529 
risk scores, Richard Anney for providing us the quality controlled GWAS summary 530 
statistics and Mick O’Donovan for his advice regarding the use of GWAS summary 531 
statistics.  532 
26 
 
REFERENCES 533 
1. Polderman TJC, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, et al. (2015) Meta-analysis 534 
of the heritability of human traits based on fifty years of twin studies. Nat Genet 47: 702. 535 
2. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, et al. (2019) Discovery of the first genome-536 
wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 51: 63-75. 537 
3. Ripke S, Consortium SWGotPG (2014) Biological insights from 108 schizophrenia-associated genetic 538 
loci. Nature 511: 421-427. 539 
4. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, et al. (2019) Identification of common genetic 540 
risk variants for autism spectrum disorder. Nat Genet 51: 431-444. 541 
5. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, et al. (2018) Genome-wide association 542 
analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat 543 
Genet 50: 668-681. 544 
6. Thapar A, Cooper M, Rutter M (2017) Neurodevelopmental disorders. Lancet Psychiatry 4: 339-346. 545 
7. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. (2018) Analysis of shared heritability 546 
in common disorders of the brain. Science 360. 547 
8. Wray NR, Lee SH, Mehta D, Vinkhuyzen AAE, Dudbridge F, et al. (2014) Research Review: Polygenic 548 
methods and their application to psychiatric traits. J Child Psychol Psychiatry 55: 1068-1087. 549 
9. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, et al. (2017) Comparison of Sociodemographic 550 
and Health-Related Characteristics of UK Biobank Participants With Those of the General 551 
Population. Am J Epidemiol 186: 1026-1034. 552 
10. Martin AR, Daly MJ, Robinson EB, Hyman SE, Neale BM (2019) Predicting Polygenic Risk of 553 
Psychiatric Disorders. Biol Psychiatry 86: 97-109. 554 
11. Dudbridge F (2013) Power and predictive accuracy of polygenic risk scores. PLoS Genet 9: 555 
e1003348. 556 
12. Riglin L, Collishaw S, Thapar AK, Dalsgaard S, Langley K, et al. (2016) Association of Genetic Risk 557 
Variants With Attention-Deficit/Hyperactivity Disorder Trajectories in the General Population. 558 
JAMA Psychiatry 73: 1285-1292. 559 
13. So H-C, Sham PC (2016) Exploring the predictive power of polygenic scores derived from genome-560 
wide association studies: a study of 10 complex traits. Bioinformatics 33: 886-892. 561 
14. Jansen AG, Dieleman GC, Jansen PR, Verhulst FC, Posthuma D, et al. (2019) Psychiatric Polygenic 562 
Risk Scores as Predictor for Attention Deficit/Hyperactivity Disorder and Autism Spectrum 563 
Disorder in a Clinical Child and Adolescent Sample. Behav Genet. 564 
15. Richardson TG, Harrison S, Hemani G, Davey Smith G (2019) An atlas of polygenic risk score 565 
associations to highlight putative causal relationships across the human phenome. Elife 8. 566 
16. Leppert B, Havdahl A, Riglin L, Jones HJ, Zheng J, et al. (2019) Association of Maternal 567 
Neurodevelopmental Risk Alleles With Early-Life Exposures. JAMA Psychiatry. 568 
17. Loe IM, Feldman HM (2007) Academic and Educational Outcomes of Children With ADHD. J Pediat 569 
Psychol 32: 643-654. 570 
18. Stergiakouli E, Martin J, Hamshere ML, Heron J, St Pourcain B, et al. (2017) Association between 571 
polygenic risk scores for attention-deficit hyperactivity disorder and educational and cognitive 572 
outcomes in the general population. Int J Epidemiol 46: 421-428. 573 
19. Rhodes JD, Pelham WE, Gnagy EM, Shiffman S, Derefinko KJ, et al. (2016) Cigarette smoking and 574 
ADHD: An examination of prognostically relevant smoking behaviors among adolescents and 575 
young adults. Psychol Addict Behav 30: 588-600. 576 
20. Flory K, Molina BS, Pelham WE, Jr., Gnagy E, Smith B (2006) Childhood ADHD predicts risky sexual 577 
behavior in young adulthood. J Clin Child Adolesc Psychol 35: 571-577. 578 
21. Hanc T, Cortese S (2018) Attention deficit/hyperactivity-disorder and obesity: A review and model 579 
of current hypotheses explaining their comorbidity. Neurosci Biobehav Rev 92: 16-28. 580 
27 
 
22. Schachar R, Taylor E, Wieselberg M, Thorley G, Rutter M (1987) Changes in Family Function and 581 
Relationships in Children Who Respond to Methylphenidate. J Am Acad Child Adolesc 582 
Psychiatry 26: 728-732. 583 
23. Lifford KJ, Harold GT, Thapar A (2009) Parent-child hostility and child ADHD symptoms: a 584 
genetically sensitive and longitudinal analysis. J Child Psychol Psychiatry 50: 1468-1476. 585 
24. Harold GT, Leve LD, Barrett D, Elam K, Neiderhiser JM, et al. (2013) Biological and rearing mother 586 
influences on child ADHD symptoms: revisiting the developmental interface between nature 587 
and nurture. J Child Psychol Psychiatry 54: 1038-1046. 588 
25. Neumeyer AM, Cano Sokoloff N, McDonnell EI, Macklin EA, McDougle CJ, et al. (2018) Nutrition 589 
and Bone Density in Boys with Autism Spectrum Disorder. J Acad Nutr Diet 118: 865-877. 590 
26. Ekhlaspour L, Baskaran C, Campoverde KJ, Sokoloff NC, Neumeyer AM, et al. (2016) Bone Density 591 
in Adolescents and Young Adults with Autism Spectrum Disorders. J Autism Dev Disord 46: 592 
3387-3391. 593 
27. Neumeyer AM, O'Rourke JA, Massa A, Lee H, Lawson EA, et al. (2015) Brief report: bone fractures 594 
in children and adults with autism spectrum disorders. J Autism Dev Disord 45: 881-887. 595 
28. Mostafa GA, Al-Ayadhi LY (2012) Reduced serum concentrations of 25-hydroxy vitamin D in 596 
children with autism: relation to autoimmunity. J Neuroinflammation 9: 201. 597 
29. Macova L, Bicikova M, Ostatnikova D, Hill M, Starka L (2017) Vitamin D, neurosteroids and autism. 598 
Physiol Res 66: S333-s340. 599 
30. Reitan R (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept 600 
Motor Skills: 271-276. 601 
31. Aleman A, Hijman R, de Haan EH, Kahn RS (1999) Memory impairment in schizophrenia: a meta-602 
analysis. Am J Psychiatry 156: 1358-1366. 603 
32. Wolwer W, Gaebel W (2002) Impaired Trail-Making Test-B performance in patients with acute 604 
schizophrenia is related to inefficient sequencing of planning and acting. J Psychiatr Res 36: 605 
407-416. 606 
33. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of 607 
the evidence. Neuropsychol 12: 426-445. 608 
34. Zalla T, Joyce C, Szoke A, Schurhoff F, Pillon B, et al. (2004) Executive dysfunctions as potential 609 
markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res 121: 610 
207-217. 611 
35. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS (2004) Cognitive deficits in relatives of 612 
patients with schizophrenia: a meta-analysis. Schizophr Res 71: 285-295. 613 
36. Perianez JA, Rios-Lago M, Rodriguez-Sanchez JM, Adrover-Roig D, Sanchez-Cubillo I, et al. (2007) 614 
Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: sample 615 
comparisons and normative data. Arch Clin Neuropsychol 22: 433-447. 616 
37. Zhou RY, Wang JJ, Sun JC, You Y, Ying JN, et al. (2017) Attention deficit hyperactivity disorder may 617 
be a highly inflammation and immune-associated disease (Review). Mol Med Rep 16: 5071-618 
5077. 619 
38. Galecki P, Talarowska M (2018) Inflammatory theory of depression. Psychiatr Pol 52: 437-447. 620 
39. Savitz J, Harrison NA (2018) Interoception and Inflammation in Psychiatric Disorders. Biol 621 
Psychiatry Cogn Neurosci Neuroimaging 3: 514-524. 622 
40. Tonacci A, Billeci L, Ruta L, Tartarisco G, Pioggia G, et al. (2017) A systematic review of the 623 
association between allergic asthma and autism. Minerva Pediatr 69: 538-550. 624 
41. Billeci L, Tonacci A, Tartarisco G, Ruta L, Pioggia G, et al. (2015) Association Between Atopic 625 
Dermatitis and Autism Spectrum Disorders: A Systematic Review. Am J Clin Dermatol 16: 371-626 
388. 627 
42. Schans JV, Cicek R, de Vries TW, Hak E, Hoekstra PJ (2017) Association of atopic diseases and 628 
attention-deficit/hyperactivity disorder: A systematic review and meta-analyses. Neurosci 629 
Biobehav Rev 74: 139-148. 630 
28 
 
43. Hackinger S, Prins B (2018) Evidence for genetic contribution to the increased risk of type 2 631 
diabetes in schizophrenia.  8: 252. 632 
44. Taylor AE, Jones HJ, Sallis H, Euesden J, Stergiakouli E, et al. (2018) Exploring the association of 633 
genetic factors with participation in the Avon Longitudinal Study of Parents and Children. Int 634 
J Epidemiol. 635 
45. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G (2018) Collider scope: when selection 636 
bias can substantially influence observed associations. Int J Epidemiol 47: 226-235. 637 
46. Lawlor DA, Tilling K, Davey Smith G (2016) Triangulation in aetiological epidemiology. Int J 638 
Epidemiol 45: 1866-1886. 639 
47. Davey Smith G, Ebrahim S (2001) Epidemiology--is it time to call it a day? Int J Epidemiol 30: 1-11. 640 
48. World Health Organisation WHO (2003) Investing in mental health. Geneva. 641 
49. Mitchell R, Elsworth B, Mitchell R, Raistrick C, Paternoster L, et al. (2019) MRC IEU UK Biobank 642 
GWAS pipeline version 2. 643 
https://doi.org/10.5523/bris.pnoat5528cxo5520u5552p5526ynfaekeigi. 644 
50. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, et al. (2010) Robust relationship inference 645 
in genome-wide association studies. Bioinformatics 26: 2867-2873. 646 
51. Martin J, Taylor MJ, Rydell M, Riglin L, Eyre O, et al. (2018) Sex-specific manifestation of genetic 647 
risk for attention deficit hyperactivity disorder in the general population. J Child Psychol 648 
Psychiatry. 649 
52. Richardson TG, Harrison S, Hemani G, Davey Smith G (2019) An atlas of polygenic risk score 650 
associations to highlight putative causal relationships across the human phenome. eLife 8: 651 
e43657. 652 
53. Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, et al. (2018) Genomic Dissection of Bipolar 653 
Disorder and Schizophrenia, Including 28 Subphenotypes. Cell 173: 1705-1715.e1716. 654 
54. Millard LAC, Davies NM, Gaunt TR, Davey Smith G, Tilling K (2017) Software Application Profile: 655 
PHESANT: a tool for performing automated phenome scans in UK Biobank. Int J Epidemiol. 656 
55. Millard LAC, Davies NM, Tilling K, Gaunt TR, Davey Smith G (2019) Searching for the causal effects 657 
of body mass index in over 300 000 participants in UK Biobank, using Mendelian 658 
randomization. PLoS Genet 15: e1007951. 659 
56. Zheng J, Richardson TG, Millard LAC, Hemani G, Elsworth BL, et al. (2018) PhenoSpD: an integrated 660 
toolkit for phenotypic correlation estimation and multiple testing correction using GWAS 661 
summary statistics. Gigascience 7. 662 
57. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, et al. (2019) Genome-wide meta-analysis 663 
of depression identifies 102 independent variants and highlights the importance of the 664 
prefrontal brain regions. Nat Neurosci 22: 343-352. 665 
  666 
29 
 
SUPPORTING INFORMATION 667 
 668 
S1 Fig. Top associated outcomes with PRS for attention deficit/hyperactivity disorder 669 
(ADHD), autism spectrum disorder (ASD), schizophrenia (SCZ), bipolar disorder (BP) 670 
and major depressive disorder (MDD) across different p-value thresholds for SNP 671 
inclusion (5x10-8 – 1x10-2). 672 
S2 Fig. Schematic description of collider bias and confounding when testing for 673 
associations between genetic liability for psychiatric disorders and adulthood 674 
outcomes in UK Biobank. 675 
S3 Fig. Histograms of standardized PRS for Attention deficit/ hyperactivity disorder (ADHD, 676 
nSNP=10), autism spectrum disorder (ASD, nSNP=2), schizophrenia (SCZ, nSNP=113), major 677 
depression (MDD, nSNP=39) and bipolar disorder (BP, nSNP=8). 678 
S1 Table. Overview of UK Biobank categories with total number of outcomes per 679 
category and number of associated outcomes with polygenic risk scores passing the 680 
significance threshold (p<2.55x10-6). (ADHD- attention defict/ hyperactivity disorder, 681 
ASD- autism spectrum disorder, SCZ- schizophrenia, MDD- major depressive 682 
disorder, BP- bipolar disorder) 683 
S2 Table. Correlation matrix of polygenic risk scores (p<5x10-8). Correlation 684 
coefficients are displayed on the left side, p-values on the right side of the table. 685 
(ADHD- attention defict/ hyperactivity disorder, ASD- autism spectrum disorder, SCZ- 686 
schizophrenia, MDD- major depressive disorder, BP- bipolar disorder) 687 
S3 Table. PRS-pheWAS results for association of generic risk of 5 common 688 
psychiatric disorders with 23,004 outcomes in UK Biobank. Genetic risk is defined as 689 
weighted sum of all genome-wide significant risk alleles for each disorder in 334,976 690 
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participants of the UK Biobank. Estimates were generated by PHESANT. Results for 691 
continuous outcomes are the standard deviation change of inverse-rank normal 692 
transformed outcome per 1 SD higher PRS. 693 
S4 Table. PRS-pheWAS follow-up and sensitivity results for selected continuous 694 
outcomes. Genetic risk is defined as weighted sum of all genome-wide significant risk 695 
alleles for each disorder in 334,976 participants of the UK Biobank. Estimates were 696 
generated by linear regression on the original variable scale per 1 SD higher PRS.  697 
S5 Table. PRS-pheWAS sensitivity results for association of generic risk of 5 common 698 
psychiatric disorders with 23,004 outcomes in UK Biobank, additionally adjusted for 699 
genetic batch and assessment centre . Genetic risk is defined as weighted sum of all 700 
genome-wide significant risk alleles for each disorder in 334,976 participants of the 701 
UK 702 
S6 Table. Number of strongly associated traits with PRS for attention-703 
deficit/hyperactivity disorder (ADHD), autism spectrum disorder 704 
(ASD),  schizophrenina (SCZ), major depressive disorder (MDD) and bipolar disorder 705 
(BP) at different p-value thresholds for PRS calculation. 706 
S7 Table. PRS-PheWAS results for association of genetic risk of major depression 707 
with 23,004 outcomes in UK Biobank. Genetic risk is defined as weighted sum of all 708 
genome-wide significant risk alleles for major depression using full GWAS summary 709 
statistics as reported in Wray et al. 2019 and GWAS summary statistics excluding the 710 
UK Biobank and 23andMe sample from the mentioned study (noUKB). Estimates were 711 
generated by PHESANT. Results for continuous outcomes are the standard deviation 712 
change of inverse-rank normal transformed outcome per 1SD higher PRS. 713 
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S8 Table. Expected bias of effect estimates due to association of exposure and 714 
outcome variable with participation in a study (collider) under simplyfied assumptions. 715 
S9 Table. Number of SNPs included in polygenic risk scores for attention-716 
deficit/hyperactivity disorder (ADHD), autism spectrum disorder 717 
(ASD),  schizophrenina (SCZ), major depressive disorder (MDD) and bipolar disorder 718 
(BP) at different p-value thresholds. 719 
S10 Table. Spearman correlation coefficients of polygenic risk scores computed at 720 
different p-value thresholds. 721 
S1 Text. Sensitivity analysis for autism spectrum disorder 722 
S2 Text. UK Biobank outcomes description 723 
